Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives $21.00 Consensus Price Target from Analysts

Telix Pharmaceuticals Limited (NASDAQ:TLX) has earned an average rating of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $20.40.

A number of brokerages recently commented on TLX. Citigroup decreased their target price on Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a report on Tuesday, July 7th. Wedbush reissued an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday, July 6th. Royal Bank Of Canada downgraded Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a report on Friday, July 17th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Friday.

Telix Pharmaceuticals Stock Performance

TLX stock opened at $10.92 on Wednesday. The company’s 50-day moving average is $10.36 and its 200-day moving average is $9.11. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. Telix Pharmaceuticals has a 1 year low of $6.28 and a 1 year high of $16.94.

Key Stories Impacting Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Telix reported Q2 2026 revenue of US$247 million, signaling strong commercial momentum and continued growth across its oncology radiopharmaceutical portfolio. Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
• Positive Sentiment: The company announced the first patient was dosed in the Phase 3 LUTEON trial of TLX250-Tx for renal cancer, a meaningful de-risking event for a key pipeline asset. Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
• Positive Sentiment: Telix also said the first patient was dosed in another Phase 3 renal cancer study, reinforcing investor confidence in the company’s late-stage development pipeline. Telix doses first patient in phase 3 renal cancer trial
• Positive Sentiment: Telix published results from the ProstACT SELECT study in Cancers, adding scientific validation for its PSMA-targeting TLX591-Tx program. TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
• Positive Sentiment: Market commentary and investor-focused coverage suggested the results and pipeline updates could support continued interest in Telix shares. Are Telix shares a buy hold or sell following results?
• Neutral Sentiment: Additional news articles and trading chatter highlighted Telix as a top topic on investor forums, but these items mainly reflected attention around the company rather than a new fundamental catalyst. Tuesday’s HotCopper trends

Insider Buying and Selling

In other Telix Pharmaceuticals news, CEO Christian Behrenbruch purchased 33,435 shares of the firm’s stock in a transaction on Wednesday, April 29th. The stock was acquired at an average price of $14.87 per share, for a total transaction of $497,178.45. Following the purchase, the chief executive officer owned 20,742,935 shares of the company’s stock, valued at $308,447,443.45. This trade represents a 0.16% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Rhumbline Advisers raised its holdings in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares during the last quarter. Bank of America Corp DE boosted its stake in Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares during the last quarter. XTX Topco Ltd bought a new stake in Telix Pharmaceuticals during the 4th quarter worth approximately $89,000. XY Capital Ltd bought a new stake in Telix Pharmaceuticals during the 1st quarter worth approximately $120,000. Finally, IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter worth approximately $213,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.